Literature DB >> 34463279

Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient.

Arrieta Vinaixa Aranzazu1, Víctor Morillas-Lahuerta1, María Blanco De Tord1, José-Manuel Carrascosa Carrillo1.   

Abstract

Entities:  

Year:  2021        PMID: 34463279      PMCID: PMC8572685          DOI: 10.1684/ejd.2021.4087

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   2.805


× No keyword cloud information.
  10 in total

1.  Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma.

Authors:  Mariam B Totonchy; Harib H Ezaldein; Christine J Ko; Jennifer N Choi
Journal:  JAMA Dermatol       Date:  2016-05-01       Impact factor: 10.282

2.  Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma.

Authors:  Mikio Ohtsuka; Takako Miura; Tatsuhiko Mori; Masato Ishikawa; Toshiyuki Yamamoto
Journal:  JAMA Dermatol       Date:  2015-07       Impact factor: 10.282

3.  Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome.

Authors:  Juan Ruiz-Bañobre; Ihab Abdulkader; Urbano Anido; Luis León; Rafael López-López; Jorge García-González
Journal:  APMIS       Date:  2017-03       Impact factor: 3.205

4.  Anti-PD1-induced psoriasis: a study of 21 patients.

Authors:  J Bonigen; C Raynaud-Donzel; J Hureaux; N Kramkimel; A Blom; G Jeudy; A-L Breton; T Hubiche; C Bedane; D Legoupil; A Pham-Ledard; J Charles; M Pérol; E Gérard; P Combemale; D Bonnet; M-L Sigal; E Mahé
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-11-07       Impact factor: 6.166

Review 5.  Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.

Authors:  Vincent Sibaud; Nicolas Meyer; Laurence Lamant; Emmanuelle Vigarios; Julien Mazieres; Jean Pierre Delord
Journal:  Curr Opin Oncol       Date:  2016-07       Impact factor: 3.645

6.  Case of de novo psoriasis possibly triggered by nivolumab.

Authors:  Susumu Murata; Sakae Kaneko; Yuji Harada; Noriaki Aoi; Eishin Morita
Journal:  J Dermatol       Date:  2016-05-14       Impact factor: 4.005

7.  IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy.

Authors:  Jonathan L Curry; Adi Diab; Daniel Johnson; Anisha B Patel; Marc I Uemura; Van A Trinh; Natalie Jackson; Chrystia M Zobniw; Michael T Tetzlaff; Patrick Hwu
Journal:  Cancer Immunol Res       Date:  2019-04-17       Impact factor: 11.151

8.  Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

Authors:  Kenneth B Gordon; Andrew Blauvelt; Kim A Papp; Richard G Langley; Thomas Luger; Mamitaro Ohtsuki; Kristian Reich; David Amato; Susan G Ball; Daniel K Braun; Gregory S Cameron; Janelle Erickson; Robert J Konrad; Talia M Muram; Brian J Nickoloff; Olawale O Osuntokun; Roberta J Secrest; Fangyi Zhao; Lotus Mallbris; Craig L Leonardi
Journal:  N Engl J Med       Date:  2016-06-08       Impact factor: 91.245

Review 9.  Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia.

Authors:  Matthias M Weber; Christian Fottner
Journal:  Oncol Res Treat       Date:  2018-04-26       Impact factor: 2.825

Review 10.  Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.

Authors:  Shrujal Baxi; Annie Yang; Renee L Gennarelli; Niloufer Khan; Ziwei Wang; Lindsay Boyce; Deborah Korenstein
Journal:  BMJ       Date:  2018-03-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.